Skip to main content
Leiden University
Scholarly Publications
Home
Submit
About
Select Collection
All collections
Academic speeches
Dissertations
Faculty of Archaeology
Faculty of Governance and Global Affairs
Faculty of Humanities
Faculty of Science
Faculty of Social and Behavioural Sciences
Leiden Journals, Conference Proceedings and Books
Leiden Law School
Leiden University Press
Medicine / Leiden University Medical Centre (LUMC)
Research output UL
Search box
Your Search
Enabled Filters
(-)
= Cho, B.C.
Sort Options
Date (year)
Author / Creator
Title
Refine Results
Resource Type
Article / Letter to editor
(5)
+
-
Availability
Open access
(3)
+
-
Metadata Only
(2)
+
-
Creation Date
2020
(2)
+
-
Faculty
Leiden University Medical Center (LUMC)
(5)
+
-
Collection
Medicine / Leiden University Medical Centre (LUMC)
(5)
+
-
Author
Cho, B.C.
(5)
+
-
Han, J.Y.
(3)
+
-
Kim, D.W.
(3)
+
-
Baas, P.
(2)
+
-
Bruns, R.
(2)
+
-
Chen, Y.M.
(2)
+
-
Cortot, A.B.
(2)
+
-
Felip, E.
(2)
+
-
Forster, M.D.
(2)
+
-
Garassino, M.C.
(2)
+
-
Garon, E.B.
(2)
+
-
Griesinger, F.
(2)
+
-
Gubens, M.A.
(2)
+
-
Herbst, R.S.
(2)
+
-
Jensen, E.H.
(2)
+
-
Majem, M.
(2)
+
-
Mazieres, J.
(2)
+
-
Monnet, I.
(2)
+
-
Novello, S.
(2)
+
-
Paik, P.K.
(2)
+
-
Park, K.
(2)
+
-
Patel, J.D.
(2)
+
-
Perez-Gracia, J.L.
(2)
+
-
Raskin, J.
(2)
+
-
Sakai, H.
(2)
+
-
Samkari, A.
(2)
+
-
Smit, E.F.
(2)
+
-
Su, W.C.
(2)
+
-
Veillon, R.
(2)
+
-
Viteri, S.
(2)
+
-
Yang, J.C.H.
(2)
+
-
Show more
Language
en
(5)
+
-
Search results
(1 - 5 of 5)
show grid
show list
save search
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
Five year survival update from KEYNOTE-010
Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations
Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1-positive, advanced non-small-cell lung cancer in the KEYNOTE-010 study
Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study